Objective: Limited evidence is available about the early cardiac manifestation of Fabry disease (FD) in children. We aimed to evaluate cardiac involvement in children with FD by analysing serial structural and electrocardiographic changes.
Methods: The data were acquired from 22 children with FD [11 males; median age 9.8 (ranging 2.5–16) years]. Seven patients (5 males) were on enzyme replacement therapy (ERT) with Agalasidase alpha. Echocardiography, ECG and 24-h ECG monitoring recordings were acquired during routine annual clinical controls. ECG data were compared to a group of age-and gender-matched controls.
Results: At baseline, ECG and ECHO parameters of left ventricular mass were similar in both males and females. Three boys (all were on ERT) developed left ventricular hypertrophy (LVH) during two-year follow-up. The progression to LVH was accompanied by the appearance of frequent ventricular premature beats in two cases and supraventricular premature beats (SPBs) with T wave inversion in one case. T wave inversion and SPBs were detected in two younger relatives of a patient with LVH, in the absence of detectable LVH. Seven out of 22 patients had T wave abnormalities. Five of them were males (p = 0.03) all carrying the N215S mutation (p = 0.03). At baseline, median PR intervals were prolonged in FD subjects compared to controls [143 (122–177) vs. 122 (82–165) ms; p < 0.0001].
Conclusions: Cardiac complications of FD become apparent in childhood as subtle changes with slow but detectable progression over time, with males more frequently affected than females. Progression of LVH was apparent in three children despite ERT.
Left Ventricular Hypertrophy Left Ventricular Mass Enzyme Replacement Therapy Fabry Disease Wave Inversion
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Enzyme replacement therapy
24-h ECG monitoring
Left ventricular hypertrophy
Supraventricular premature beats
Ventricular premature beats
This is a preview of subscription content, log in to check access.
We thank the metabolic nurses and the cardiology technicians at Addenbrooke’s Hospital for their help with collating data and performing cardiac ECHO and Holter monitoring.
Aryana A, Fifer MA, Ruskin JN, Mela T (2008) Short PR interval in the absence of preexcitation: a characteristic finding in a patient with Fabry disease. Pacing Clin Electrophysiol 31:782–783PubMedCrossRefGoogle Scholar
Brady RO, Schiffmann R (2000) Clinical features of and recent advances in therapy for Fabry disease. JAMA 248:2771–2775CrossRefGoogle Scholar
Cybulla M, Walter K, Neumann HP et al (2007) Fabry disease: demographic data since introduction of enzyme replacement therapy. Dtsch Med Wochenschr 132:1505–1509PubMedCrossRefGoogle Scholar
Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346PubMedCrossRefGoogle Scholar
Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458PubMedCrossRefGoogle Scholar
Dickinson DF, Scott O (1984) Ambulatory electrocardiographic monitoring in 100 healthy teenage boys. Br Heart J 51:179–183PubMedCrossRefGoogle Scholar
Douglas PS, Garcia MJ, Haines DE et al (2011) ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Soc Echocardiogr 24:229–267PubMedCrossRefGoogle Scholar
Elliott PM, Kindler H, Shah JS et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360PubMedCrossRefGoogle Scholar
Elliott P, Baker R, Pasquale F et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey. Heart 97:1957–1960PubMedCrossRefGoogle Scholar
Eng CM, Niehaus DJ, Desnick RJ (1993a) Molecular analysis of classical and variant phenotypes. Pediatr Res 33:128AGoogle Scholar
Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ (1993b) Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53:1186–1197PubMedGoogle Scholar
Frustaci A, Chimenti C (2007) Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation 116:350–351CrossRefGoogle Scholar
Jastrzebski M, Bacior B, Dimitrow PP, Kawecka-Jaszcz K (2006) Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace 8:1045–1047PubMedCrossRefGoogle Scholar
Kampmann C, Baehner F, Whybra C et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668–1674PubMedCrossRefGoogle Scholar
Kampmann C, Linhart A, Baehner F et al (2008a) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367–373PubMedCrossRefGoogle Scholar
Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008b) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463–469PubMedCrossRefGoogle Scholar
Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 22:709–714PubMedCrossRefGoogle Scholar
Kleinert J, Dehout F, Schwarting A et al (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19:782–787PubMedCrossRefGoogle Scholar
Linhart A, Palecek T, Bultas J et al (2000) New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 139:1101–1108PubMedCrossRefGoogle Scholar
Linhart A, Magage S, Palecek T, Bultas J (2002) Cardiac involvment in Fabry disease. Acta Paediatr Suppl 91:15–20PubMedCrossRefGoogle Scholar
Mehta J, Tuna N, Moller JH, Desnick RJ (1977) Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J 93:699–705PubMedCrossRefGoogle Scholar
Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996PubMedCrossRefGoogle Scholar
Monserrat L, Gimeno-Blanes JR, Marin F et al (2007) Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50:2399–2403PubMedCrossRefGoogle Scholar
Namdar M, Kampmann C, Steffel J et al (2010) PQ interval in patients with Fabry disease. Am J Cardiol 105:753–756PubMedCrossRefGoogle Scholar
Namdar M, Steffel J, Vidovic M et al (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 97:485–490PubMedCrossRefGoogle Scholar
O`Connor M, McDaniel N, Brady W (2008) The pediatric electrocardiogram Part I. Am J Emerg Med 26:221–228CrossRefGoogle Scholar
O'Mahony C, Coats C, Cardona M et al (2011) Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace 13:1781–1788PubMedCrossRefGoogle Scholar
Patel MR, Cecchi F, Cizmarik M et al (2011) Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol 57:1093–1099PubMedCrossRefGoogle Scholar
Pochis WT, Litzow JT, King BG, Kenny D (1994) Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol 74:203–204PubMedCrossRefGoogle Scholar
Ramaswami U, Whybra C, Parini R et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92PubMedCrossRefGoogle Scholar
Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M (2012) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 81:485–490PubMedCrossRefGoogle Scholar
Ries M, Ramaswami U, Parini R et al (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162:767–772PubMedCrossRefGoogle Scholar
Ries M, Clarke JTR, Whybra C et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932PubMedCrossRefGoogle Scholar
Rijnbeek PR, Witsenburg M, Schrama E, Hess J, Kors JA (2001) New normal limits for the paediatric electrocardiogram. Eur Heart J 22:702–711PubMedCrossRefGoogle Scholar
Rijnbeek PR, Herpen G, Kapusta L, Harkel DJ, Witsenburg M, Kors JA (2008b) Electrocardiographic criteria for left ventricular hypertrophy in children. Pediatr Cardiol 29:923–928PubMedCrossRefGoogle Scholar
Sachdev B, Takenaka T, Teraguchi H et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407–1411PubMedCrossRefGoogle Scholar
Scott O, Williams GJ, Fiddler GI (1980) Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 44:304–308PubMedCrossRefGoogle Scholar
Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842–846PubMedCrossRefGoogle Scholar
Southall DP, Johnston F, Shinebourne EA, Johnston PGB (1981) 24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children. Br Heart J 45: 281–291PubMedCrossRefGoogle Scholar
Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561–2567PubMedCrossRefGoogle Scholar
Tøndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767–776PubMedCrossRefGoogle Scholar
Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227PubMedCrossRefGoogle Scholar
Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529PubMedCrossRefGoogle Scholar